Glaxosmithkline | GSK - Gross Profit On Sales



Glaxosmithkline reported GBP5.83B in Gross Profit on Sales for its fiscal quarter ending in June of 2025.


Gross Profit On Sales Change Date
AbbVie USD 9.34B 1.36B Mar/2025
Amgen USD 6.17B 624M Jun/2025
AstraZeneca USD 11.98B 637M Jun/2025
Aurora Cannabis CAD 27.95M 18.6M Jun/2025
Bausch Health Companies USD 1.77B 208M Jun/2025
Bristol-Myers Squibb USD 8.9B 714M Jun/2025
Canopy Growth CAD 18.04M 6.06M Jun/2025
Corcept Therapeutics USD 191M 36.19M Jun/2025
Drreddys Laboratories INR 48.63B 425M Jun/2025
Eli Lilly USD 13.11B 2.61B Jun/2025
GlaxoSmithKline GBP 5.82B 229M Jun/2025
Glaxosmithkline GBP 5.83B 232M Jun/2025
J&J USD 14.6B 816M Mar/2025
Merck USD 12.99B 224M Jun/2025
Novartis USD 11.51B 1.12B Jun/2025
Pacira USD 125.91M 8.71M Jun/2025
Perrigo USD 362.9M 29.4M Jun/2025
Pfizer USD 10.88B 248M Jun/2025
Prestige Brands USD 140.33M 29.68M Jun/2025
Roche Holding CHF 11.69B 48M Dec/2024
Sanofi EUR 7.74B 26M Jun/2025
Supernus Pharmaceuticals USD 127.81M 6.25M Jun/2025
Takeda JPY 722.01B 50.69B Jun/2025
Teva Pharmaceutical Industries USD 2.1B 188M Jun/2025
Zoetis USD 1.78B 180M Jun/2025